BEIJING CHUNLIZHENGDA MEDICAL INSTRUMENTS CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.6 HKD | +0.52% |
|
+8.21% | -6.90% |
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- The company's attractive earnings multiples are brought to light by a P/E ratio at 12.75 for the current year.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -6.90% | 1.05B | - | ||
| +12.55% | 129B | A- | ||
| -9.23% | 10.77B | A- | ||
| +2.17% | 9.05B | C | ||
| +19.58% | 7.38B | C | ||
| +21.85% | 4.88B | B+ | ||
| +7.38% | 3.41B | C- | ||
| -0.34% | 3.07B | B- | ||
| -5.07% | 2.24B | - | - | |
| -4.22% | 2.12B | - |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 1858 Stock
- Ratings Beijing Chunlizhengda Medical Instruments Co., Ltd.
